Filing Details
- Accession Number:
- 0000950170-24-012456
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-07 20:32:33
- Reporting Period:
- 2024-02-05
- Accepted Time:
- 2024-02-07 20:32:33
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1650648 | 4D Molecular Therapeutics Inc. | FDMT | Biological Products, (No Disgnostic Substances) (2836) | 473506994 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1971608 | Young Robert Kim | C/O 4D Molecular Therapeutics, Inc. 5858 Horton Street, Suite 455 Emeryville CA 94608 | Chief Medical Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-02-05 | 12,000 | $18.66 | 13,595 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-02-05 | 12,000 | $30.05 | 1,595 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-02-05 | 6,000 | $15.78 | 7,595 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-02-05 | 6,000 | $30.05 | 1,595 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-02-05 | 6,000 | $8.04 | 7,595 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-02-05 | 6,000 | $30.05 | 1,595 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-02-05 | 552 | $30.05 | 1,043 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-02-05 | 12,000 | $0.00 | 120,000 | $18.66 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-02-05 | 6,000 | $0.00 | 6,000 | $15.78 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-02-05 | 6,000 | $0.00 | 6,000 | $8.04 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 138,000 | 2030-11-08 | No | 4 | M | Direct | |
| 64,000 | 2032-01-31 | No | 4 | M | Direct | |
| 54,000 | 2032-08-31 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 11, 2023.
- 25% of the shares subject to the option vest on the first anniversary measured from October 7, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest and become exercisable in equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
- The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
- The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Billionaire Hedge Funds
